Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.12968/jowc.2023.32.Sup9.S4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluating the Real-World Safety of Icosapent Ethyl Versus Omega-3 Polyunsaturated Fatty Acid in Nationwide US Veterans Cohort: Examining Atrial Fibrillation and Bleeding Endpoints.
Clin Drug Investig
January 2025
Department of Medicine, Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Perelman School of Medicine, 423 Guardian Drive, Philadelphia, PA, 19104, USA.
Purpose: The REDUCE-IT randomized trial demonstrated a cardiovascular benefit of icosapent ethyl (IPE) but also raised potential safety signals for atrial fibrillation (AF) and serious bleeding. We aimed to evaluate the real-world safety of IPE versus mixed omega-3 polyunsaturated fatty acid (OM-3) formulations.
Methods: This retrospective active comparator new-user cohort study compared rates of new-onset AF and major bleeding (MB) among adult new users of IPE versus OM-3 in 2020-2024 US Veterans Affairs data.
Challenges to Cardiovascular Health Among Female U.S. Veterans and Future Implications: A Scoping Review.
Mil Med
January 2025
Veterans Affairs Quality Scholars Fellowship, Ralph H. Johnson VA Medical Center, Charleston, SC 29412, USA.
Introduction: Cardiovascular disease (CVD) is the leading cause of death for women in the United States, and U.S. female Veterans have higher rates of CVD compared to civilian women.
View Article and Find Full Text PDFHip Region Stress Fracture in South Korean Military Recruits: Private's Fracture.
Mil Med
January 2025
Department of Orthopedic Surgery, Armed Forces Daejeon Hospital, Daejeon, 34059, Korea.
Introduction: This study aims to analyze the characteristics of hip region stress fractures (HSFs) within a South Korean military cohort and identify the associated risk factors to provide insights for treatment and prevention strategies. Additionally, we will report the epidemiologic data and clinical outcomes of treating HSF within the second largest military hospital.
Materials And Methods: Between January 2022 and December 2023, this retrospective case series revised all HSF patients' medical records to analyze demographic and epidemiologic data and clinical progress.
Is There a Role for Hormonal Therapy in Men with Oligoasthenoteratozoospermia (OAT)?
J Clin Med
December 2024
Global Andrology Forum, Moreland Hills, OH 44022, USA.
Hormonal factors play an essential role as an underlying causative factor of oligoasthenoteratozoospermia (OAT), and these patients can benefit from hormonal medications that modulate the hypothalamic-pituitary-gonadal axis. This review aims to outline the various medications used as hormonal therapy in treating infertile men with OAT. This manuscript focuses on essential hormonal evaluation, identifying men who would benefit from treatment, selecting the appropriate medication, determining the duration of therapy, and evaluating hormonal treatment outcomes.
View Article and Find Full Text PDFEverolimus Through Plasmatic Concentrations in Cancer Patients: Prospective Longitudinal Observational Multicentric Study (DIANA-1 Project).
J Clin Med
December 2024
Pharmacy Department, Institut Català Oncologia (ICO), Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet Llobregat, 08908 Barcelona, Spain.
Everolimus, an oral inhibitor of the mammalian target of rapamycin (mTOR), is actually used to prevent organ transplant rejection and treat metastatic breast, renal, and neuroendocrine cancers. Despite significant pharmacokinetic variability among patients, routine therapeutic drug monitoring (TDM) is not commonly used in oncology. The aim of this multicenter, prospective observational cohort study is to assess the prevalence of everolimus minimum concentration at a steady state (Cminss) falling outside the therapeutic range (10-26.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!